INNATE AND ADAPTIVE IMMUNITY TO HCV IN HUMAN PREGNANCY

人类妊娠期对 HCV 的先天性和适应性免疫

基本信息

  • 批准号:
    9021550
  • 负责人:
  • 金额:
    $ 31.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-02-07 至 2019-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is the most common blood-borne infection in the United States, with an overall prevalence of ~2%, and an estimated 200 million chronically infected people worldwide. A substantial body of evidence, including work from our laboratory, supports the concept that early events in the coordination and nature of multi-cellular immune responses are critical in determining whether the virus is cleared or whether persistence is established. However, despite the fact that approximately 40,000 pregnancies occur each year in HCV-infected women, little is known about the immunopathogenesis or correlates of protective immunity in this setting, in part because pregnant women with chronic HCV have hitherto been excluded from studies of immunity. For the first time, we present evidence that trophoblasts, specialized cells of the placenta that play important roles in embryo implantation and interaction with decidualized maternal uterus, can take up HCV proteins as well as respond to a viral product of hepatitis C (known as a pathogen-associated molecular pattern or PAMP) by producing high levels of Type III IFNs. These intriguing results corroborate the recent studies demonstrating genetic associations with single nucleotide polymorphisms that encode interferon lambda 3 and spontaneous recovery from HCV. Furthermore, we have identified HCV-specific CD8+ T cells within the maternal-fetal interface that we hypothesize demonstrate versatile functional attributes that prevent transmission in the majority of cases. We will also study how antigen-presenting cells in the decidua cross- present HCV antigens from trophoblasts and prime CD8+ T cells within the maternal fetal interface. Thus, our proposal seeks to mechanistically understand the different cells and signals that underpin HCV transmission versus protection.
描述(由申请人提供):丙型肝炎病毒(HCV)是美国最常见的血源性感染,总体患病率约为2%,全球估计有2亿慢性感染者。大量证据,包括我们实验室的工作,支持多细胞免疫反应的协调和性质的早期事件在确定病毒是否被清除或是否建立持久性方面至关重要的概念。然而,尽管事实上,每年约有40,000例妊娠发生在HCV感染的女性中,但对这种情况下的免疫发病机制或保护性免疫的相关性知之甚少,部分原因是慢性HCV孕妇迄今为止一直被排除在免疫研究之外。这是第一次,我们提出的证据表明,滋养层细胞,胎盘的专门细胞,在胚胎植入和与蜕膜化的母体子宫的相互作用中发挥重要作用,可以采取HCV蛋白,以及响应丙型肝炎病毒的产品(称为病原体相关的分子模式或PAMP)通过产生高水平的III型IFN。这些有趣的结果证实了最近的研究表明编码干扰素λ 3的单核苷酸多态性与HCV自发恢复的遗传相关性。此外,我们已经确定了母胎界面内的HCV特异性CD8+ T细胞,我们假设它们表现出在大多数情况下阻止传播的多功能属性。我们还将研究蜕膜中的抗原呈递细胞如何交叉呈递来自滋养层的HCV抗原和母胎界面内的初始CD8+ T细胞。因此,我们的建议旨在从机制上理解支持HCV传播与保护的不同细胞和信号。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARGARET G PETROFF其他文献

MARGARET G PETROFF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARGARET G PETROFF', 18)}}的其他基金

Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
  • 批准号:
    10396646
  • 财政年份:
    2020
  • 资助金额:
    $ 31.86万
  • 项目类别:
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
  • 批准号:
    10215585
  • 财政年份:
    2020
  • 资助金额:
    $ 31.86万
  • 项目类别:
Endocrine regulation of maternal immunity in pregnancy
孕期母体免疫力的内分泌调节
  • 批准号:
    10116259
  • 财政年份:
    2020
  • 资助金额:
    $ 31.86万
  • 项目类别:
Endocrine regulation of maternal immunity in pregnancy
孕期母体免疫力的内分泌调节
  • 批准号:
    9979498
  • 财政年份:
    2020
  • 资助金额:
    $ 31.86万
  • 项目类别:
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
  • 批准号:
    10617856
  • 财政年份:
    2020
  • 资助金额:
    $ 31.86万
  • 项目类别:
Shared Placenta/Tumor Antigens and Maternal Immunity
共享胎盘/肿瘤抗原和母体免疫
  • 批准号:
    9316903
  • 财政年份:
    2017
  • 资助金额:
    $ 31.86万
  • 项目类别:
INNATE AND ADAPTIVE IMMUNITY TO HCV IN HUMAN PREGNANCY
人类妊娠期对 HCV 的先天性和适应性免疫
  • 批准号:
    8654226
  • 财政年份:
    2014
  • 资助金额:
    $ 31.86万
  • 项目类别:
Maternal Central Immune Tolerance to the Fetal-Placental Unit
母体对胎儿胎盘单位的中枢免疫耐受
  • 批准号:
    8038448
  • 财政年份:
    2010
  • 资助金额:
    $ 31.86万
  • 项目类别:
Maternal Central Immune Tolerance to the Fetal-Placental Unit
母体对胎儿胎盘单位的中枢免疫耐受
  • 批准号:
    7774089
  • 财政年份:
    2010
  • 资助金额:
    $ 31.86万
  • 项目类别:
FUNCTIONAL COOPERATION BETWEEN TROPHOBLAST HLA-G AND B7 FAMILY
滋养层 HLA-G 和 B7 家族之间的功能合作
  • 批准号:
    7699715
  • 财政年份:
    2008
  • 资助金额:
    $ 31.86万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 31.86万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 31.86万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 31.86万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 31.86万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 31.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 31.86万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 31.86万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 31.86万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 31.86万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 31.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了